I-Mab
Market Cap
$235.66M
P/E Ratio
-5.65
EPS
$-0.51
Dividend Yield
0.00%
52-Week Range
$0.59 — $6.79
Volume
892.60K
Avg Volume
1.85M
Beta
1.46
Get alerted when IMAB hits your target price.
Free — enter your email to get started
P/E (TTM)
-5.65
Forward P/E
—
PEG Ratio
0.33
P/S (TTM)
0.00
P/B (TTM)
6.88
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.07%
ROA (TTM)
-0.03%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
0.01
Current Ratio
8.09
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.39%
EPS Growth (5Y)
-0.46%
Sales Growth (3Y)
-0.23%
Sales Growth (5Y)
+9.76%
EPS Est (This Year)
$-3.62
EPS Est (Next Year)
$-2.91
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$16.10
Price Target Range
Consensus Target: $7.67(166.3% upside)
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2020-01-17
Employees
32
CEO
Xi-Yong Fu
Index Membership
—
Website
https://www.i-mabbiopharma.com
I-Mab (IMAB) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $235.66M, a P/E ratio of -5.65, IMAB is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare IMAB against other stocks using dozens of fundamental and technical filters.
I-Mab (IMAB) has a trailing twelve-month (TTM) P/E ratio of -5.65. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, I-Mab (IMAB) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
I-Mab (IMAB) has a market capitalization of $235.66 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.